Journal article
Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia
KE Mate, KP Kerr, D Pond, EJ Williams, J Marley, P Disler, H Brodaty, PJ Magin
Drugs Aging | ADIS INT LTD | Published : 2015
Abstract
CONCLUSIONS: There is considerable scope for the improvement of prescribing practices in the elderly, and particularly those with dementia. Importantly, level 1 anticholinergics have been identified as major contributors to the anticholinergic load in people with dementia. Longitudinal studies are required to determine the effects of increased and decreased anticholinergic load on cognitive function and other clinical outcomes for people with dementia.BACKGROUND: Elderly people, particularly those with dementia, are sensitive to adverse anticholinergic drug effects. This study examines the prevalence of anticholinergic medication, and anticholinergic load and its predictors, in community-dwe..
View full abstractGrants
Funding Acknowledgements
[ "The authors thank the project officers and research nurses involved in this project for their skilled assistance, and the patient and GP participants for their involvement. This study was supported by the Australian Government's National Health and Medical Research Council (grant ID#351220).", "Dimity Pond has received financial support for speaking from Alzheimer's Australia, and has served on advisory boards for Pfizer, Eli Lilly, and Nutricia within the past 3 years. Henry Brodaty has been a consultant, advisory board member, and/or sponsored speaker for Eli Lilly, Merck, Baxter, Sanofi, Servier, and Tau Therapeutics. Karen Mate, Karen Kerr, Evan Williams, John Marley, Peter Disler, and Parker Magin have no conflict of interest to report." ]